LEGAL PROCEEDINGS
−Removed: know of no material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business,
+Added: March 13, 2024, a shareholder class action complaint was filed in the United States District Court for the Southern District of New York.
+Added: The complaint is captioned Blum v.
+Added: Anavex Life Sciences, Corp.
+Added: et al., case number 1:24-cv-01910, and names the Company and Christopher
+Added: Missling as Defendants.
+Added: The complaint alleges violations of the Securities and Exchange Act of 1934 resulting from disclosures and statements
+Added: made about certain clinical trials for ANAVEX ® 2-73.
+Added: The Company believes the complaint is without merit.
+Added: The Company is
+Added: vigorously pursuing its defenses and a potential dismissal of all claims asserted in the lawsuit.
+Added: know of no other material pending legal or governmental proceedings, other than ordinary routine litigation incidental to our business,
to which our Company or our subsidiaries are a party or of which any of their property is subject.
−Removed: There are no proceedings in
−Removed: which any of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares,
−Removed: or any associate of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries’ interest.
−Removed: There have been no material changes to the
−Removed: risk factors discussed in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended
−Removed: September 30, 2023, filed with the SEC on November 27, 2023.
+Added: There are no other proceedings in which
+Added: any of our directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, or any associate
+Added: of such persons, is an adverse party or has a material interest adverse to our or our subsidiaries’ interest.
+Added: There have been no material changes to the risk factors
+Added: discussed in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023,
+Added: filed with the SEC on November 27, 2023.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.